Torrent Pharmaceuticals · NSE: TORNTPHARM · BSE: 500420
Q4 FY24 results · Jan–Mar 2024
Torrent Pharmaceuticals reported revenue from operations of ₹2,745.00 crore (up 10.2% from Q4 FY23) and net profit of ₹449.00 crore (up 56.4% from Q4 FY23) for Q4 FY24 (Jan–Mar 2024), on a consolidated basis.
| Item | Q4 FY24 | Q4 FY23 | YoY | Q3 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,745.00 | 2,491.00 | +10.2% | 2,732.00 | +0.5% |
| Other income | 31.00 | 9.00 | +244.4% | (33.00) | Turned profit |
| Total income | 2,776.00 | 2,500.00 | +11.0% | 2,699.00 | +2.9% |
| Profit before tax | 631.00 | 433.00 | +45.7% | 631.00 | +0.0% |
| Net profit for the period | 449.00 | 287.00 | +56.4% | 443.00 | +1.4% |
| EPS, basic (₹) | 13.27 | 8.48 | +56.5% | 13.10 | +1.3% |
| Net margin (%) | 16.4 | 11.5 | 16.2 |
| Item | Q4 FY24 | Q4 FY23 | YoY | Q3 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,143.00 | 1,920.00 | +11.6% | 2,123.00 | +0.9% |
| Other income | 76.00 | 26.00 | +192.3% | (11.00) | Turned profit |
| Total income | 2,219.00 | 1,946.00 | +14.0% | 2,112.00 | +5.1% |
| Profit before tax | 530.00 | 328.00 | +61.6% | 430.00 | +23.3% |
| Net profit for the period | 410.00 | 219.00 | +87.2% | 297.00 | +38.0% |
| EPS, basic (₹) | 12.12 | 6.46 | +87.6% | 8.78 | +38.0% |
| Net margin (%) | 19.1 | 11.4 | 14.0 |
Consolidated
- Filed with BSE
- 25 May 2024, 14:20 IST
- Board meeting
- 24 May 2024
- Period
- 01 Jan 2024 to 31 Mar 2024
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 25 May 2024, 14:20 IST
- Board meeting
- 24 May 2024
- Period
- 01 Jan 2024 to 31 Mar 2024
- Review status
- Audited
- Source
- XBRL filing on BSE